Oregon Hemp Testing and Potency – Quick Reference Guide OREGON: The Oregon Liquor and Cannabis Commission (OLCC) and the Oregon Department of Agriculture (ODA) receive numerous questions regarding testing and potency limits for hemp items in Oregon. These requirements depend on who manufactures the hemp item and where the item will be sold. OLCC and Read the full article...
http://dlvr.it/SZHzVq
Friday, September 30, 2022
Wednesday, September 28, 2022
Global Legal Cannabis Market Size, Trends & Analysis Report 2022-2030: Regulatory Scenario, Consumption Pattern, Potential Trade Opportunities, Case Studies, End-users, Competitive Landscape – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Legal Cannabis Market Size, Share & Trends Analysis Report by Source (Marijuana, Hemp), by Derivative (CBD, THC), by End Use (Medical Use, Recreational Use, Industrial Use), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global legal cannabis market size is expected to reach USD 134.4 billion by 2030 and is expected to expand at a CAGR of 25.3% from 2022 to 2030
The increased legalization across different nations of the usage of cannabis-derived products has gained a lot of popularity. Medical cannabis-based has been used in the treatment of various indications like epileptic seizures, nausea related to chemotherapy, anxiety, and other brain-related diseases.
Several studies are being conducted for CBD products in various indications. The medical fraternity has slowly increased acceptance of medical cannabis as well as marijuana and its derivatives owing to its legalization by the governments. Some countries like Canada, the U.S., and Uruguay have legalized its recreational use along with medicinal use.
Adult use and recreational use of marijuana is readily available in some of the countries' markets, thereby increasing adoption and market growth. The COVID-19 pandemic has impeded the growth of the market. Supply chain disruptions and a surge in panic buying scenarios led to the increase in the demand-supply gap, thereby affecting the market growth. However, it is expected to grow post-pandemic with the increased support from governments and ever-increasing demand.
Based on source, the marijuana segment accounted for the largest revenue share of over 70.0% in 2021 and is expected to exhibit the fastest growth rate during the forecast period. Marijuana is easily available and consumers are becoming more aware of its therapeutic properties alongside the more traditional recreational uses.
It has been seen to reduce stress and relieve pain, thereby improving sleep irregularities. The decriminalization and legalization of marijuana usage have resulted in a marked reduction in illegal activities surrounding marijuana. CBD is quite potent when it comes to derivatives of the cannabis plant, thus it has emerged as the largest derivative segment with a revenue share of over 65.0% in 2021.
The adoption of CBD-based products is increasing rapidly owing to the non-psychoactive nature of the derivative, thereby fueling market growth. In addition, positive attitudes of the medical fraternity toward CBD-based medicines are further propelling the segment growth.
In addition, the others segment is anticipated to grow at the fastest rate during the forecast period owing to rising awareness and acceptance regarding the derivatives, along with increasing geographies sanctioning the use of various cannabinoids for medical and other purposes.
North America dominated the market with a revenue share of over 65.0% in 2021 owing to increasing acceptance of cannabis for medical purposes across the region and changing consumer perception toward cannabis. In addition, the presence of prominent cannabis companies in the North American region is boosting the market growth.
Moreover, the Asia region is anticipated to grow at the fastest rate owing to the increasing number of countries sanctioning the use of cannabis, mainly for medical purposes.
Legal Cannabis Market Report Highlights
The market growth can be attributed to the increasing legalization of cannabis across the globe.
The marijuana source segment dominated the market in 2021 owing to the increasing adoption of marijuana for medical as well as adult use.
The CBD derivative segment dominated the market in 2021 owing to the increasing number of countries sanctioning the use of CBD for medical as well as other purposes.
by end use, the medical use segment dominated the market in 2021 owing to the rising geriatric population and increasing demand for cannabis for various medical purposes such as the management of chronic pain, mental disorders, chemotherapy-induced nausea and vomiting, and neurological disorders.
North America dominated the market in 2021 owing to the growing demand and positive attitude toward cannabis in this region.
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Global Legal Cannabis Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.2 Market Restraint Analysis
3.4 Global Legal Cannabis Industry: History Of Medical Use Of Cannabis
3.5 Global Legal Cannabis Industry: History Of Industrial Use Of Cannabis
3.6 Global Legal Cannabis Industry: Number Of Clinical Trials, by Region
3.7 Global Legal Cannabis Industry: Legalization Timeline
3.7.1 Legalization Landscape (Timeline)
3.7.2 U.S. Legalization Landscape
3.7.3 Global Legal Cannabis Regulatory Scenario, by Country
3.7.3.1 U.S.
3.7.3.1.1 Overview
3.7.3.1.2 Cultivation/Production
3.7.3.1.3 Regulatory Bodies Involved
3.7.3.2 Canada
3.7.3.3 Germany
3.7.3.4 Italy
3.7.3.5 Croatia
3.7.3.6 The Netherlands
3.7.3.7 Czech Republic
3.7.3.8 Poland
3.7.3.9 Switzerland
3.7.3.10 Australia
3.7.3.11 Uruguay
3.7.3.12 Colombia
3.7.3.13 Argentina
3.7.3.14 Chile
3.7.3.15 Mexico
3.7.3.16 Israel
3.8 Global Legal Cannabis Industry: Consumption Pattern Analysis, by Region
3.8.1 Consumption Pattern Analysis, by Region
3.8.2 Estimated Number Of Cannabis Users From 2016 To 2026, by Country
3.8.3 Estimated Number Of Medical Marijuana Users From 2016 To 2026, by Country
3.9 Global Legal Cannabis Industry: Potential Trade Opportunity
3.9.1 Trade Opportunity Analysis, by Region
3.9.2 Global Legal Cannabis Trade Route
3.9.3 Global Hemp Trade Route
3.9.4 Countries Importing and Exporting Medical Cannabis (Flower)
3.9.5 Countries Importing and Exporting Hemp Seeds
3.9.6 Countries Importing and Exporting Hemp Seed Oil
3.10 Global Legal Cannabis Industry: Seed To Shelf Story
3.10.1 Section Description
3.10.1.1 Cultivators and Growers
3.10.1.2 Manufacturers and Producers
3.10.1.3 Testers
3.10.1.4 Wholesalers and Distributors
3.10.1.5 Retailers
3.10.2 Supply Chain Analysis
3.10.2.1 Profit Margin Estimation
3.11 Global Legal Cannabis Industry: Country Case Studies
3.11.1 U.S.
3.11.1.1 Legalization Of Cannabis
3.11.1.2 Reason For Legalization
3.11.1.3 Scenario After Legalization and Consumer Attitudes
3.11.1.4 Competitive Landscape Post Legalization
3.11.2 Canada
3.11.3 Thailand
3.11.4 South Africa
3.11.5 Uruguay
Chapter 4 Global Legal Cannabis Market: Source Estimates & Trend Analysis
4.1 Segment Dashboard
4.2 Global Legal Cannabis Market: Source Movement Analysis, (USD Million) 2021 & 2030
4.2.1 Marijuana
4.2.1.2 Flowers
4.2.1.3 Oil and Tinctures
4.2.2 Hemp
4.2.2.2 Hemp CBD
4.2.2.3 Supplements
4.2.2.4 Industrial Hemp
Chapter 5 Global Legal Cannabis Market: Derivative Estimates & Trend Analysis
5.1 Segment Dashboard
5.2 Global Legal Cannabis Market: Derivative Movement Analysis, USD Million, 2021 & 2030
5.2.1 CBD
5.2.2 THC
5.2.3 Others
Chapter 6 Global Legal Cannabis Market: End-Use Estimates & Trend Analysis
6.1 Segment Dashboard
6.2 Global Legal Cannabis Market: End-Use Movement Analysis, USD Million, 2021 & 2030
6.2.1 Medical Use
6.2.1.1 Medical Use Market Estimates and Forecasts, 2016 - 2030 (USD Million)
6.2.1.2 Cancer
6.2.1.3 Chronic Pain
6.2.1.4 Depression and Anxiety
6.2.1.5 Arthritis
6.2.1.6 Diabetes
6.2.1.7 Glaucoma
6.2.1.8 Migraines
6.2.1.9 Epilepsy
6.2.1.10 Multiple Sclerosis
6.2.1.11 Aids
6.2.1.12 Amyotrophic Lateral Sclerosis
6.2.1.13 Alzheimer's
6.2.1.14 Post Traumatic Stress Disorder (Ptsd)
6.2.1.15 Parkinson's
6.2.1.16 Tourette's
6.2.1.17 Others
6.2.2 Recreational Use
6.2.3 Industrial Use
Chapter 7 Global Legal Cannabis Market: Competitive Analysis
7.1 Company Market Position Analysis
7.2 Strategic Framework
Chapter 8 Global Legal Cannabis Market: Regional Estimates & Trend Analysis: by Source, Derivative, and End Use
8.1 Regional Market Snapshot
8.2 Global Legal Cannabis Market: Regional Movement Analysis, USD Million, 2021 & 2030, USD Million
Chapter 9 Competitive Landscape
Gw Pharmaceuticals, plc
Aurora Cannabis, Inc.
Aphria, Inc. (Prior to Merger With Tilray)
Cronos Group
Tilray
Sundial Growers, Inc.
Insys Therapeutics, Inc.
the Scotts Company LLC
Vivo Cannabis Inc.
Cara Therapeutics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/uxsik0
http://dlvr.it/SZ8B7S
http://dlvr.it/SZ8B7S
Tuesday, September 27, 2022
Aelis Farma: Availability of the 2022 Half-year Financial Report
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces that its half-year financial report has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers).
It can be consulted on the Company's website, www.aelisfarma.com, in the section Investors/Documentation/Reports.
***
About AELIS FARMA
Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). These new molecular entities hold great potential in the treatment of many brain diseases. CB1-SSi were developed by Aelis Farma on the basis of the discovery of a new natural defense mechanism of the brain made by the team of Dr. Pier Vincenzo Piazza, CEO of the Company, when he was Director of the Inserm Magendie Neurocenter in Bordeaux. For these discoveries, Dr. Piazza was awarded the Inserm Grand Prix and the Grand Prix of Neurology of the French Academy of Sciences, which are among the most prestigious French prizes in medicine and neurology.
Aelis Farma is developing two first-in-class drug candidates that are at the clinical stage, AEF0117 and AEF0217, and has a portfolio of innovative CB1-SSi for the treatment of other diseases associated with a dysregulation of the activity of the CB1 receptor.
AEF0117, which targets the disorders due to excessive cannabis use (addiction and psychosis), has shown indications of efficacy in a phase 2a clinical trial and has entered a phase 2b clinical trial in the United States in Q2 2022. Aelis Farma has an exclusive option-license agreement with Indivior PLC, a leading pharmaceutical company in the treatment of addiction, for the development and commercialization of AEF0117 for disorders due to excessive cannabis use. As part of this agreement, Aelis Farma received $30 million (option payment). If Indivior exercises the license option at the end of the phase 2b, Aelis Farma will receive a $100 million license fee (potentially in 2024) and up to $340 million in additional payments contingent on the achievement of development, regulatory and commercial milestones as well as, royalties on net sales of AEF0117 ranging between 12% and 20%.
AEF0217, which targets various cognitive disorders including those associated with Down syndrome, has finished recruitments of its phase 1 program in healthy volunteers and will start in Q4 2022 a phase 1/2 study in Down syndrome subjects. This compound has undergone an extensive preclinical proof-of-concept program using highly innovative assessing cognitive functions. In this context, AEF0217 has demonstrated its ability to completely reverse cognitive deficits observed in several animal models of neurodevelopmental disorders, such as Down syndrome and Fragile X syndrome, as well as in models of certain cognitive deficits associated with aging.
Based in Bordeaux, within the Magendie Neurocenter, Aelis Farma has a team of 23 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.
For more information: www.aelisfarma.com
ISIN: FR0014007ZB4
Ticker: AELIS
B Compartment of Euronext Paris
Disclaimer
Forward-looking statements
Some information contained in this press release are forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance or achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and detailed in Chapter 3 "Risk Factors" of Aelis Farma's registration document approved by the Autorité des marchés financiers on 14 January 2022 under number I.22-003.
These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
http://dlvr.it/SZ5HV0
http://dlvr.it/SZ5HV0
Monday, September 26, 2022
Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction (the “Company” or “Anebulo”), today announced positive interim data from the first two cohorts of Part B of its ongoing Phase 2 clinical trial evaluating ANEB-001 as a treatment for ACI.
The first two cohorts were challenged with 21 mg of THC, dosed orally (twice the THC dose used in Part A). Subjects then received 30mg (cohort 1) or 10mg (cohort 2) oral doses of ANEB-001, or matching placebo. The interim data available from Part B include pharmacokinetics, key pharmacodynamic outcomes, and blinded safety data. Based on these data, subjects challenged with a higher 21 mg oral THC dose and treated with placebo showed greater central nervous system (CNS) effects than observed in Part A with 10.5 mg THC. The effects included a substantial increase in feeling high and body sway, decreased alertness, and slightly increased heart rate compared to baseline. In contrast, treatment of subjects with 10 mg or 30 mg ANEB-001 led to significant and sustained reductions in the visual analog scale (VAS) feeling high score (p < 0.001), improvement in the VAS alertness scale (p < 0.01), and a reduction in THC-induced body sway (p < 0.01), compared to placebo.
In addition, 100% of subjects given 21 mg THC with placebo in Cohorts 1 and 2 met the VAS threshold for feeling high ( >20 mm on the 100 mm VAS scale) compared to only 1 subject per group treated with ANEB-001 at 10 mg or 30 mg doses. Although the THC-induced increase in heart rate in this study was small, there was a trend towards improvement with ANEB-001 compared to placebo. The 10 mg and 30 mg ANEB-001 doses had similar effects to previous higher doses used in Part A, despite doubling the THC dose. Pharmacokinetic data from Part A and the first two cohorts of Part B confirmed rapid absorption and dose-related plasma exposure for oral ANEB-001.
“These new Part B data showed that 10mg of ANEB-001 reversed key symptoms of ACI, comparing favorably to our Part A data showing similar effects with 50mg and 100mg. The 10mg data is even more impressive considering we doubled the THC challenge to 21mg in that cohort,” said Simon Allen, Chief Executive Officer of Anebulo. “Using lower doses of ANEB-001 to reduce ACI symptoms should allow us to optimize tolerability, while providing an even more favorable cost of goods if ANEB-001 is approved. We are currently exploring the effects of delayed dosing to better understand real-world conditions. In this circumstance, we challenge subjects with THC one hour before administering ANEB-001. With no FDA approved therapeutic, ACI often requires lengthy emergency department stays with expensive follow-on interventions for neuropsychiatric complications such as anxiety and acute psychosis. We believe ANEB-001 will play a critical role in reducing the burden of ACI for the patient and the healthcare system.”
The Phase 2 study is being conducted in healthy adult occasional cannabis users at the Centre for Human Drug Research (CHDR) in the Netherlands. Results of Part A of the study, announced in July 2022, showed positive effects of 50 mg or 100 mg of ANEB-001 in reducing the effects of a 10.5 mg oral THC dose. Part B of the study is an adaptive study design intended to evaluate lower doses of ANEB-001 at higher levels of THC. We intend to enroll a total of at least 6 cohorts in Part B, with up to 15 subjects per cohort, randomized 2:1 to active versus placebo.
Based on Part A and interim Part B results, the Company is continuing Part B of the study at CHDR to further evaluate the dose response and the effects of separating the doses of THC and ANEB-001. Enrollment of the third cohort of Part B is ongoing. Anebulo is currently collaborating with the Model-Informed Drug Development (MIDD) group at FDA to develop a PK/PD model that will be designed to predict optimal doses for treatment of ACI subjects. Preparations are ongoing for an observational study in ACI subjects in the emergency department setting to further support the PK/PD model and ANEB-001 development. Based on blinded safety data, adverse events in Cohorts 1 and 2 were mild and transient, except for two cases of moderate dizziness in Cohort 1 likely attributable to THC.
About ANEB-001
Our lead product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, to address the unmet medical need for a specific antidote for ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment candidate that we anticipate will reverse the symptoms of ACI, in most cases within 1 hour of administration. ANEB-001 is protected by one issued patent and rights to one patent application covering various methods of use of the compound and delivery systems. We began a Phase 2 proof-of-concept trial for ANEB-001 in December 2021 in the Netherlands and announced positive Phase 2 Part A proof-of-concept topline data on July 5, 2022 and positive Part B data on September 26, 2022.
About Acute Cannabinoid Intoxication (ACI)
Symptoms of ACI can include increased somnolence, impaired cognition and perception, disorientation, anxiety, and acute psychosis. According to DSM-5, a diagnosis of cannabinoid intoxication should include recent history of cannabinoid use, clinically considerable behavioral or psychological changes, such as euphoria, impaired judgment and motor skills, which have taken place since cannabinoid exposure.
About Visual Analogue Scale (VAS)
VAS is a validated tool commonly used to help rate the intensity of certain subjective sensations and feelings, such as feeling high. For example, for rating feeling high, the visual analog scale is typically a straight line with one end meaning not high and the other end meaning extremely high. A subject marks a point on the line that matches how high they feel.
About CHDR
The Centre for Human Drug Research (CHDR) is an independent institute that specializes in cutting-edge early-stage clinical drug research. Combining innovative methods and technologies, state-of-the-art facilities, and talented, motivated researchers helps CHDR maximize their clients’ success. In addition, CHDR places the highest priority on their subjects’ comfort and safety, and they play an active role in helping educate the medical and clinical research communities.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, is currently in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) to evaluate its utility in reversing the negative effects of acute cannabinoid intoxication within one hour of administration. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.
Forward-Looking Statements
Statements contained in this press release that are not statements of historical fact are forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by words such as “anticipate,” “believe,” “designed,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms. Forward-looking statements include statements regarding Anebulo’s intentions, beliefs, projections, outlook, analyses or current expectations regarding: our belief that using lower doses of ANEB-001 to reduce ACI symptoms should allow us to optimize safety and tolerability, while providing an even more favorable cost of goods if ANEB-001 is approved; our belief that ANEB-001 will play a critical role in reducing the burden of ACI for the patient and the healthcare system; the PK/PD model we are developing in collaboration with MIDD and its expected design and capabilities; are planned observational study in ACI subjects in the emergency department setting and its expected benefits; statements related to the remainder of Part B of the Phase 2 study; You are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to a number of risks, uncertainties and assumptions, including, but not limited to: initial and interim results from clinical studies are not necessarily indicative of results that may be observed in the future; clinical trial site challenges that may impact the expected timing of the Company’s ongoing clinical trials, including challenges related to the ongoing COVID-19 pandemic; the timing and success of clinical trials and potential safety and other complications thereof; future supply or manufacturing issues; our ability to successfully commercialize and distribute ANEB-001, if approved; any negative effects on the Company’s business and product development plans caused by or associated with COVID-19 or geopolitical issues; and our need for additional capital. These and other risks are described in under the “Risk Factors” heading of Anebulo’s most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on September 9, 2022. All forward-looking statements made in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Except as required by law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect new information, future events, changed conditions or otherwise after the date of this press release.
http://dlvr.it/SZ11t4
http://dlvr.it/SZ11t4
Friday, September 23, 2022
High Tide Ranks 21st Out of 448 In Globe and Mail’s Annual Ranking of Canada’s Top Growing Companies With 1970% Revenue Growth Over Three Years
CALGARY, Alberta--(BUSINESS WIRE)--High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, is pleased to announce that it has ranked 21st out of 430 companies on the 2022 Report on Business ranking of Canada’s Top Growing Companies.
Canada’s Top Growing Companies ranks Canadian companies based on their three-year revenue growth. High Tide earned its spot with a three-year growth rate of 1,970%.
This follows the Company’s 2021 ranking of 82nd out of 448 companies with a three-year growth rate of 733%.
“The Globe and Mail, Canada’s newspaper of record, has, for the second year in a row, recognized High Tide’s exponential growth, ranking us 21st out of 430 on its annual ranking of Canada’s Top Growing Companies due to our three-year revenue growth rate of 1,970%. Receiving this honour two years running is a testament to our ability to continue to execute our strategic growth plan despite ongoing market challenges,” said Raj Grover, President and Chief Executive Officer of High Tide. “Since opening our first bricks-and-mortar store in October 2018, High Tide has grown to over 1,300 employees, 140 retail stores today across Canada and a global portfolio of high-performing e-commerce assets. The months ahead hold exciting opportunities for High Tide, including further strategic expansion of our retail locations in Canada, the accelerated rollout of our proprietary Fastendr retail kiosks, the expansion of our white label product offerings in select provinces, and the launch of our Cabana Elite paid membership program, driving further revenue growth,” added Mr. Grover.
Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to celebrate the boldest entrepreneurial achievement by identifying and bringing the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application process and fulfill requirements. In total, 430 companies earned a spot on this year’s ranking.
The full list of 2022 winners along with editorial coverage is published in the October issue of the Report on Business magazine. The list is now available and online here.
“Canada's Top Growing Companies recognizes the tremendous ambition and innovation of entrepreneurs in Canada," says Dawn Calleja, Editor of Report on Business magazine. “The next generation of Canadian businesses can draw inspiration from this ranking.”
“In an uncertain world, the success stories of the companies marked in this year’s Report on Business magazine’s list of Top Growing Companies are a beacon of optimism,” says Phillip Crawley, Publisher and Chief Executive Officer of The Globe and Mail. “The Globe and Mail congratulates them on their achievements.”
https://youtu.be/taDQn677OWY
ABOUT THE GLOBE AND MAIL
The Globe and Mail is Canada’s foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 5.9 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.3 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.
ABOUT HIGH TIDE
High Tide is a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets. The Company is the largest Canadian retailer of recreational cannabis as measured by revenue, with 140 current locations spanning Ontario, Alberta, British Columbia, Manitoba, and Saskatchewan. The Company is also North America’s first cannabis discount club retailer, under the Canna Cabana banner, which is the single-largest cannabis retail brand in Canada with additional locations under development across the country. High Tide’s portfolio also includes retail kiosks and smart locker technology – Fastendr™. High Tide has been serving consumers for over a decade through its established e-commerce platforms including Grasscity.com, Smokecartel.com, Dailyhighclub.com, and Dankstop.com and more recently in the hemp-derived CBD space through Nuleafnaturals.com, FABCBD.com, BlessedCBD.co.uk, BlessedCBD.de, and Amazon United Kingdom, as well as its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide has been featured in the annual Report on Business Magazine’s ranking of Canada’s Top Growing Companies in 2021 and 2022 and was named as one of the top 10 performing diversified industries stocks in the 2022 TSX Venture 50™. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain while providing a complete customer experience and maximizing shareholder value.
For more information about High Tide, please visit www.hightideinc.com and its profile pages on SEDAR at www.sedar.com and EDGAR at www.sec.gov.
Neither the TSX Venture Exchange (the “TSXV”) nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events.
The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s business; the Company’s future growth prospects and intentions to pursue one or more viable business opportunities; the development of the Company’s business and future activities following the date hereof; expectations relating to market size and anticipated growth in the jurisdictions within which the Company may from time to time operate or contemplate future operations; expectations with respect to economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; the market for the Company’s current and proposed product offerings, as well as the Company’s ability to capture market share; the Company’s strategic investments and capital expenditures, and related benefits; the distribution methods expected to be used by the Company to deliver its product offerings; the competitive landscape within which the Company operates and the Company’s market share or reach; the performance of the Company’s business and the operations and activities of the Company; the Company adding the number of additional cannabis retail store locations the Company proposes to add to the Company’s business, and the Company remaining on a positive growth trajectory; same-store sales continuing to increase in the fourth quarter of 2022 and beyond; the Company deploying Fastendr™ technology across the Company’s retail stores upon the timelines disclosed herein; the Company continuing to increase its revenue through the remainder of the year; the Company completing the development of its cannabis retail stores; the Company’s ability to generate cash flow from operations and from financing activities; the Company’s ability to obtain, maintain, and renew or extend, applicable authorizations, including the timing and impact of the receipt thereof; the realization of cost savings, synergies or benefits from the Company’s recent acquisitions, and the Company’s ability to successfully integrate the operations of any business acquired within the Company’s business; Cabana Club loyalty program membership continuing to increase; the Company hitting its forecasted revenue and sales projections for the fourth quarter of 2022 and beyond; the Company’s expectations from its Cabana Cannabis Co. white label products; the Company launching Cabana Cannabis Co. white label products in its proposed jurisdictions; the Company launching the Cabana elite program on the terms and timelines outlined herein; the anticipated effects of the Cabana elite
program on the business and operations of the Company; and the Company continuing to grow its online retail portfolio through further strategic and accretive acquisitions.
Forward-looking information in this press release are based on certain assumptions and expected future events, namely: current and future members of management will abide by the Company’s business objectives and strategies from time to time established by the Company; the Company will have sufficient working capital and the ability to obtain the financing required in order to develop and continue its business and operations; the Company will continue to attract, develop, motivate and retain highly qualified and skilled consultants and/or employees, as the case may be; no adverse changes will be made to the regulatory framework governing cannabis, taxes and all other applicable matters in the jurisdictions in which the Company conducts business and any other jurisdiction in which the Company may conduct business in the future; the Company will be able to generate cash flow from operations, including, where applicable, the distribution and sale of cannabis and cannabis products; the Company will be able to execute on its business strategy as anticipated; the Company will be able to meet the requirements necessary to obtain and/or maintain authorizations required to conduct the business; general economic, financial, market, regulatory, and political conditions, will not negatively affect the Company or its business; the Company will be able to successfully compete in the cannabis industry; cannabis prices will not decline materially; the Company will be able to effectively manage anticipated and unanticipated costs; the Company will be able to maintain internal controls over financial reporting and disclosure, and procedures in order to ensure compliance with applicable laws; general market conditions will be favourable with respect to the Company’s future plans and goals; the Company will deploy Fastendr™ technology across the Company’s retail stores upon the timelines disclosed herein; the Company will launch Cabana Cannabis Co. white label products in the jurisdictions and on the timelines outlined herein and such products will achieved the results disclosed herein; same-store sales will continue to increase in the fourth quarter of 2022 and beyond; the Company will make meaningful increases to its revenue profile; the Company will continue to increase its revenue through the fourth fiscal quarter of 2022, and the remainder of the year; the Company will remain on a positive growth trajectory; the Company will complete the development of its cannabis retail stores; the Cabana Elite program will have the anticipated effect on the business and operations of the Company; and the Company will continue to grow its online retail portfolio through further strategic and accretive acquisitions.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to attract and retain qualified members of management to grow the Company’s business and its operations;
unanticipated changes in economic and market conditions or in applicable laws; the impact of the publications of inaccurate or unfavourable research by securities analysts or other third parties; interruptions or shortages in the supply of cannabis from time to time available to support the Company’s operations from time to time; unanticipated changes in the cannabis industry in the jurisdictions within which the Company may from time to time conduct its business and operations, including the Company’s inability to respond or adapt to such changes; the Company’s inability to secure or maintain favourable lease arrangements or the required authorizations necessary to conduct the business and operations and meet its targets; the Company’s inability to secure desirable retail cannabis store locations on favourable terms; risks relating to projections of the Company’s operations; the Company’s inability to effectively manage unanticipated costs and expenses, including costs and expenses associated with product recalls and judicial or administrative proceedings against the Company; risk that the Company will not hit its forecasted revenue and sales projections for the fourth quarter of 2022, and beyond; risk that Cabana Club loyalty program membership will decrease and/or plateau; risk that the Company will be unable to deploy Fastendr™ technology across the Company’s retail stores or on the timelines disclosed herein; risk that the Company will be unable to launch Cabana Cannabis Co. white label products in the jurisdictions and on the timelines outlined herein and/or that such products will be unable to achieve the results disclosed herein; risk that same-store sales will not increase, but decease and/or plateau; risk that the Company will be unable to increase its revenue profile; risk that the Company will be unable to increase its revenue through the fourth fiscal quarter of 2022, and the remainder of the year, but that it will decease and/or plateau; risk that the Company will be unable to grow its online retail portfolio through further strategic and accretive acquisitions; risk that the Company will be unable to add additional cannabis retail store locations to the Company’s business and remain on a positive growth trajectory; risks that the Company will be unable to complete the development of any or all of its cannabis retail stores; risk that the Company will be unable to secure the proposed credit facilities, unable to utilize the proposed credit facilities on the terms and within the timelines anticipated and/or the proposed credit facilities will not have the anticipated effect on the business and operations of the Company; risk that the Company will be unable to launch the Cabana elite program on the terms and timelines outlined herein or at all; risk that the Cabana elite program will not have the anticipated effect on the business and operations of the Company.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
http://dlvr.it/SYsm5c
http://dlvr.it/SYsm5c
Thursday, September 22, 2022
Global Medicinal Cannabis Market Report 2022: Increasing Technological Advancements in Testing Cannabis Quality Bolster Sector – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Medicinal Cannabis Market, by Point of Sale, by Active Ingredient, and by Therapeutic Application, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. Medicinal cannabis, also known as medical marijuana, is used either for the treatment of diseases or to improve their Read the full article...
http://dlvr.it/SYnq1F
http://dlvr.it/SYnq1F
Wednesday, September 21, 2022
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
POTOMAC, Md.--(BUSINESS WIRE)--India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer’s disease.”
The original patent application was initiated by the University of South Florida (“USF”) and filed on July 30, 2015. On May 25, 2017, IGC entered into an exclusive license agreement with USF with respect to the patent application and the associated research conducted on Alzheimer’s disease. On January 9, 2020, the patent application was modified by the Company. Separately, on July 22, 2021, IGC announced the grant of the first patent (11,065,225) for some of that research and work. This new patent is for a continuation of that work.
The Company’s subsidiary, IGC Pharma, used some of the research to develop an oral formulation, IGC-AD1. Based on the USF research on Alzheimer’s cell lines, subject to further testing and clinical trials, testing indicates that on a dose dependent manner, the active agents in IGC-AD1 may ameliorate Aß plaque and decrease ptau, a phosphorylated protein responsible for tangles in neurons. Plaques and tangles are key hallmarks of Alzheimer’s disease. Further, testing in an Alzheimer’s mouse model showed that it improved memory as demonstrated in a Morris Water Maze test.
Based on these promising results, we initiated a Phase 1 study on safety and tolerability and in that study discovered that IGC-AD1 at specific dosing regimens had the potential to modify agitation and other neuropsychiatric symptoms in patients with Alzheimer’s dementia. Encouraged by this, our short term focus shifted to further testing IGC-AD1 as a therapeutic for treating neuropsychiatric synmptoms in Alzheimer’s, more specifically agitation. The Company recently filed a Phase 2 protocol with the U.S. Food and Drug Administration (“FDA”) for further clinical testing of the efficacy of IGC-AD1 on agitation in mild to severe Alzheimer’s.
Currently, there are no FDA approved pharmacological treatments for agitation in dementia from Alzheimer’s and about 70% of Alzheimer’s patients suffer from agitation/aggressiveness. The Company is hopeful that, subject to further trials and FDA approval, IGC-AD1 can provide relief for some of the over 55 million Alzheimer’s patients worldwide.
About IGC:
IGC has two segments: Life Sciences and Infrastructure. The Company is based in Maryland, U.S.A.
Forward-looking Statements: This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, and Quarterly Report on Form10-Q, filed with SEC on August 5, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
http://dlvr.it/SYkMbM
http://dlvr.it/SYkMbM
Tuesday, September 20, 2022
Arizona State University Study Examines Health Risks in Legal Cannabis Markets
ARIZONA: A new study urges that state and federal regulators need to take a closer look at health and safety risks of the growing medicinal and recreational cannabis market. “Cannabis regulation is unlike any agricultural commodities, food, or drugs in the U.S. Currently, there are no national-level guidelines based on conventional risk assessment methodologies or Read the full article...
http://dlvr.it/SYh00j
http://dlvr.it/SYh00j
Yuluka Health’s 2022 International Polo Open Sponsorships Are Connecting Its Holistic Wellness Products with Top Equestrians
MIAMI–(BUSINESS WIRE)–Yuluka Health Inc. is a global company with a strong social conscience that prioritizes the health and well-being of humans and animals alike. With over 30 years of experience, its team are veterans in the botanical, pharmaceutical, biotech and consumer packaged goods industries. Yuluka Health has a strong desire to adapt to the ever-shifting Read the full article...
http://dlvr.it/SYfvd2
http://dlvr.it/SYfvd2
Friday, September 16, 2022
CORRECTING and REPLACING High Tide Reports Third Quarter 2022 Financial Results Featuring a 98% Increase in Revenue and Tenth Straight Quarter of Positive Adjusted EBITDA
CALGARY, Alberta–(BUSINESS WIRE)–In the financial table Selected financial information for the three and nine months ended July 31, 2022, Loss per share (Basic), Three months ended July 31, 2022 should read: (0.04) instead of (0.05); Loss per share (Basic), Three months ended July 31 Change should read: 33% instead of 67%. The updated release reads: Read the full article...
http://dlvr.it/SYSwsH
http://dlvr.it/SYSwsH
Thursday, September 15, 2022
Burns & Levinson Hosts Sixth Annual State of the Cannabis Industry Conference in Boston on October 17, 2022
MASSACHUSETTS: Burns & Levinson will host its sixth annual “State of the Cannabis Industry” conference, which will focus on critical issues in the multibillion dollar cannabis industry, on October 17, 2022, from 8:30 a.m. to 6:00 p.m. ET. The conference will be held in person at the Westin Waltham Boston. A live stream option will Read the full article...
http://dlvr.it/SYP6rn
http://dlvr.it/SYP6rn
Wednesday, September 14, 2022
New Jersey Cannabis Regulatory Commission Issues Guidance for Workplaces
NEW JERSEY: The New Jersey Cannabis Regulatory Commission has issued guidance for workplaces as a first step towards formulating and approving standards for Workplace Impairment Recognition Expert certifications. The guidance and “Reasonable Suspicion Observation Report Form” issued by NJ-CRC is meant to support employers right to create and maintain safe work environments, and to affirm Read the full article...
http://dlvr.it/SYKpHp
http://dlvr.it/SYKpHp
Monday, September 12, 2022
Honoring Hispanic Heritage Month with Women in Cannabis, a Sit Down with Ixchel Mooney, Co-Owner of Mujeres Valley Campground
By Veronica Castillo This column honors BIPOC in Cannabis every day in every way, but this month, we celebrate the contributions of the Hispanic community in America, by celebrating National Hispanic Heritage Month (September 15- October 15). Celebration means different things to different people. Corporate America highlights the spending power of the hispanic community, I Read the full article...
http://dlvr.it/SYC86s
http://dlvr.it/SYC86s
Friday, September 9, 2022
WSLCB Investigation Finds Illegal Cannabis Sales at Two Washington Sites (Tacoma and Roy, Pierce Co.)
LCB Investigation Finds Illegal Cannabis Activity at “Vincere’s Compassion Club” and Roy’s “Red Barn Trading Post” in Tacoma and Roy (Pierce Co.) WASHINGTON: Following an investigation into unlicensed cannabis sales, Washington’s Liquor and Cannabis Board (LCB) Enforcement and Education Officers entered the two businesses that were the subject of the investigation and seized 1,300 pounds Read the full article...
http://dlvr.it/SY3kDV
http://dlvr.it/SY3kDV
Thursday, September 8, 2022
Florida Commissioner of Agriculture & Consumer Services Nikki Fried Demands DeSantis Administration Roll Back Harmful Dosage Restrictions for Medical Cannabis Patients
FLORIDA: Florida Commissioner of Agriculture and Consumer Services Nikki Fried, an independently-elected member of the Florida Cabinet, is calling on the Florida Department of Health (DOH) and its Office of Medical Marijuana Use (OMMU) to roll back extreme dosage restrictions enacted through an emergency rule on August 29th, a process that afforded less than three days advance notice Read the full article...
http://dlvr.it/SY0Zz8
http://dlvr.it/SY0Zz8
Thursday, September 1, 2022
OLCC Marijuana Violation Reclassification (SB 408) Rules Advisory Committee Meeting
Marijuana Violation Reclassification (SB 408) Rules Advisory Committee Meeting September 6, 2022 – 9:00 AM – 12:00 PM AGENDA Prior to the passage of 2021 SB 408, the OLCC engaged with industry partners to scope the violation reclassification project. Many of the violations listed in Oregon Administrative Rule chapter 845 division 25 were written in Read the full article...
http://dlvr.it/SXcYhg
http://dlvr.it/SXcYhg
Subscribe to:
Posts (Atom)